GKOS241220C70000
- 0.00
- 0.000.00%
Glaukos Newsroom
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Glaukos Is Maintained at Buy by Stifel
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Glaukos Cut to Underweight From Equal-Weight by Morgan Stanley
Glaukos Price Target Announced at $120.00/Share by Morgan Stanley
Morgan Stanley Downgrades Glaukos(GKOS.US) to Sell Rating, Maintains Target Price $120
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $153
BTIG Maintains Buy on Glaukos, Raises Price Target to $149
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $149
The Three-year Returns Have Been Splendid for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Glaukos Revolutionizes Glaucoma Treatment With IDose TR Approval
Glaukos Announces Participation in Upcoming Investor Conferences
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating
Glaukos Price Target Raised to $145 From $135 at Wells Fargo
Glaukos Third Quarter 2024 Earnings: Beats Expectations
Mizuho Securities Maintains Glaukos(GKOS.US) With Hold Rating
Uncertain Growth and Reimbursement Challenges Keep Glaukos's IDose at Hold Rating
Glaukos | 10-Q: Q3 2024 Earnings Report
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds